The toxins could potentially be used as ‘markers’ for doctors to identify Parkinson’s patients at a higher risk of developing ...

Australian-founded medical technology company SYMBYX today announced compelling results from a 72-week randomized controlled ...

Researchers have finally seen and measured the tiny alpha-synuclein oligomers that may ignite Parkinson’s disease. With the ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

This landmark trial is the largest-to-date and was only made possible because of the seminal work of Australian scientists from the ...

Those with Parkinson’s might notice multiple changes to their walking patterns, too, including smaller steps, slower speed, ...

A new study indicates that Parkinson's disease may not always start in the brain; it could possibly originate in the kidneys. Scientists at the Department of Neurology, Renmin Hospital of Wuhan ...